Absci (NASDAQ:ABSI) Shares Gap Up – What’s Next?
by Renee Jackson · The Cerbat GemAbsci Corporation (NASDAQ:ABSI – Get Free Report)’s stock price gapped up prior to trading on Thursday . The stock had previously closed at $5.30, but opened at $5.74. Absci shares last traded at $5.6410, with a volume of 803,134 shares trading hands.
Absci News Roundup
Here are the key news stories impacting Absci this week:
- Positive Sentiment: HC Wainwright raised its FY2026 EPS estimate for Absci to ($0.84) from ($0.87), indicating a slightly smaller expected loss.
- Positive Sentiment: The firm also lifted its Q3 2026 EPS estimate to ($0.22) from ($0.23), and kept Q4 2026 at ($0.22), showing incremental improvement in near-term forecasts.
- Positive Sentiment: Longer-term estimates were also nudged higher, including FY2028 EPS to $0.11 from $0.10 and FY2029 EPS to $0.09 from $0.08, reinforcing the view that Absci could turn profitable later in the forecast period.
- Neutral Sentiment: HC Wainwright’s Q1 2027, Q2 2027, Q3 2027, and Q4 2027 estimates remain mixed, with profitability still appearing uneven across quarters.
- Neutral Sentiment: Despite the upgrades, the company is still expected to post losses in the near term, so the stock remains sensitive to execution and future pipeline progress.
Analysts Set New Price Targets
A number of research analysts have issued reports on the company. Needham & Company LLC reissued a “buy” rating and set a $7.00 price objective on shares of Absci in a report on Wednesday, March 25th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Absci in a research report on Monday, April 20th. Morgan Stanley set a $4.10 price target on shares of Absci in a report on Thursday. Finally, Truist Financial upped their price objective on shares of Absci from $9.00 to $11.00 and gave the stock a “buy” rating in a research note on Friday, May 8th. Four investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Absci currently has an average rating of “Moderate Buy” and an average target price of $7.53.
Check Out Our Latest Report on Absci
Absci Price Performance
The business has a 50 day simple moving average of $3.52 and a 200 day simple moving average of $3.34. The company has a market cap of $873.82 million, a price-to-earnings ratio of -6.74 and a beta of 2.36.
Absci (NASDAQ:ABSI – Get Free Report) last released its quarterly earnings results on Thursday, May 7th. The company reported ($0.19) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.20) by $0.01. The business had revenue of $0.22 million during the quarter, compared to analysts’ expectations of $1.39 million. Absci had a negative return on equity of 66.32% and a negative net margin of 6,450.76%. As a group, sell-side analysts anticipate that Absci Corporation will post -0.82 earnings per share for the current fiscal year.
Insider Buying and Selling at Absci
In related news, insider Andreas Busch bought 100,000 shares of the company’s stock in a transaction on Thursday, March 12th. The stock was bought at an average cost of $2.29 per share, with a total value of $229,000.00. Following the completion of the purchase, the insider owned 421,446 shares in the company, valued at approximately $965,111.34. The trade was a 31.11% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through the SEC website. Corporate insiders own 10.49% of the company’s stock.
Institutional Investors Weigh In On Absci
Hedge funds and other institutional investors have recently made changes to their positions in the company. HB Wealth Management LLC lifted its holdings in Absci by 28.4% in the first quarter. HB Wealth Management LLC now owns 12,942 shares of the company’s stock valued at $39,000 after buying an additional 2,862 shares during the period. Jones Financial Companies Lllp lifted its stake in Absci by 41.9% in the third quarter. Jones Financial Companies Lllp now owns 12,317 shares of the company’s stock valued at $37,000 after buying an additional 3,638 shares during the period. Legal & General Group Plc boosted its holdings in Absci by 45.9% during the second quarter. Legal & General Group Plc now owns 11,690 shares of the company’s stock worth $30,000 after buying an additional 3,678 shares during the last quarter. SG Americas Securities LLC grew its position in shares of Absci by 20.7% during the 3rd quarter. SG Americas Securities LLC now owns 21,882 shares of the company’s stock worth $67,000 after buying an additional 3,758 shares during the period. Finally, Deutsche Bank AG grew its position in shares of Absci by 5.6% during the 4th quarter. Deutsche Bank AG now owns 92,148 shares of the company’s stock worth $322,000 after buying an additional 4,892 shares during the period. 52.05% of the stock is owned by institutional investors and hedge funds.
About Absci
Absci Corporation (NASDAQ: ABSI) is a biotechnology company that applies machine learning, synthetic biology and automation to accelerate the discovery and development of protein-based therapeutics. The company’s Integrated Drug Creation® (IDC®) platform is designed to identify and produce novel antibody and enzyme candidates at speeds and scales that traditional biopharma discovery methods cannot match. Absci works with pharmaceutical and biotechnology partners to generate, screen and optimize protein molecules for a wide range of therapeutic applications.
The core of Absci’s offering is its end-to-end discovery engine, which combines proprietary algorithms, high-throughput laboratory automation and a deep learning framework.